Abstract:Background: Nanotechnology involves the engineering of structures on a molecular level. Nanomedicine and nano-delivery systems have been designed to deliver therapeutic agents to a target site or organ in a controlled manner, maximizing efficacy while minimizing off-target effects of the therapeutic agent administered. In both reproductive medicine and obstetrics, developing innovative therapeutics is often tempered by fears of damage to the gamete, embryo or developing foetus or of negatively impacting a woman's reproductive potential. Thus, nanomedicine delivery systems may provide alternative targeted intervention strategies, treating the source of the disease and minimizing long-term consequences for the mother and/or her foetus. Objective and rationale: This review summarizes the current state of nanomedicine technology in reproductive medicine and obstetrics, including safety, potential applications, future directions and the hurdles for translation. Search methods: A comprehensive electronic literature search of PubMed and Web of Science databases was performed to identify studies published in English up until February 2020. Relevant keywords were used to obtain information regarding use of nanoparticle technology in fertility and gene therapy, early pregnancy complications (ectopic pregnancy and gestational trophoblastic disease) and obstetric complications (preeclampsia, foetal growth restriction, preterm birth and gestational diabetes) and for selective treatment of the mother or foetus. Safety of specific nanoparticles to the gamete, embryo and foetus was also investigated. Outcomes: Pre-clinical research in the development of nanoparticle therapeutic delivery is being undertaken in many fields of reproductive medicine. Non-hormonal-targeted nanoparticle therapy for fibroids and endometriosis may provide fertility-sparing medical management. Delivery of interventions via nanotechnology provides opportunities for gene manipulation and delivery in mammalian gametes. Targeting cytotoxic treatments to early pregnancy tissue provides an alternative approach to manage ectopic pregnancies and gestational trophoblastic disease. In pregnancy, nanotherapeutic delivery offers options to stably deliver silencing RNA and microRNA inhibitors to the placenta to regulate gene expression, opening doors to novel genetic treatments for preeclampsia and foetal growth restriction. Restricting delivery of teratogenic drugs to the maternal compartment (such as warfarin) may reduce risks to the foetus. Alternatively, targeted delivery of drugs to the foetus (such as those to treat foetal arrythmias) may minimize side effects for the mother. Wider implications: We expect that further development of targeted therapies using nanoparticles in a reproductive setting has promise to eventually allow safe and directed treatments for conditions impacting the health and reproductive capacity of women and for the management of pregnancy and serious pregnancy complications.

Nanotechnological approaches for the treatment of placental dysfunction: recent trends and future perspectives

Advance in Placenta Drug Delivery: Concern for Placenta-Originated Disease Therapy.

A Review of Nanotechnology for Treating Dysfunctional Placenta

Placental Therapeutic Targets and Nanodelivery Systems

Size-dependent Placental Retention Effect of Liposomes in ICR Pregnant Mice: Potential Superiority in Placenta-Derived Disease Therapy

Emerging Pharmacologic Interventions for Pre-Eclampsia Treatment

Placenta-targeted Treatment Strategies for Preeclampsia and Fetal Growth Restriction: An Opportunity and Major Challenge

Surface-Functionalized Nanoparticles as Efficient Tools in Targeted Therapy of Pregnancy Complications

Nanoparticles in pregnancy: the next frontier in reproductive therapeutics

Placental Drug Delivery to Treat Pre‐Eclampsia and Fetal Growth Restriction

A 3D Human Placenta-on-a-chip Model to Probe Nanoparticle Exposure at the Placental Barrier

Decoding the Molecular Pathways Governing Trophoblast Migration and Placental Development; a Literature Review

Nanoparticles Dysregulate the Human Placental Secretome with Consequences on Angiogenesis and Vascularization

Flow cytometric analysis of the murine placenta to evaluate nanoparticle platforms during pregnancy

Placental Drug Disposition and Its Clinical Implications

The utilization of nanotechnology in the female reproductive system and related disorders

Fetotoxicity of Nanoparticles: Causes and Mechanisms

Bidirectional Transfer Study of Polystyrene Nanoparticles across the Placental Barrier in an ex Vivo Human Placental Perfusion Model

Deciphering the Epigenetic Landscape: Placental Development and Its Role in Pregnancy Outcomes

Assessment of nanotoxicity in a human placenta-on-a-chip from trophoblast stem cells

Trophoblast-Targeted Liposomes for Placenta-Specific Drug Delivery